Yuria - Pharm




Concise Prescribing Info
Infections caused by sensitive strains of anaerobic or aerobic gm +ve microorganisms, eg, accompanied by bacteremia: nosocomial (hospital-acquired) pneumonia; community-acquired pneumonia; skin & soft tissue infections; infections caused by Enterococci, including vancomycin-resistant strains Enterococcus faecium & faecalis.
Dosage/Direction for Use
Nosocomial pneumonia, community-acquired pneumonia & skin & soft tissue infections (including forms accompanied by bacteremia) Adult & childn >12 yr 600 mg every 12 hr for 10-14 days. Childn from birth to 11 yr 10 mg/kg IV every 8 hr for 10-14 days. Enterococcal infections (including vancomycin-resistant strains & forms w/ IV bacteremia) Adult & childn >12 yr 600 mg IV every 12 hr for 14-28 days. Childn from birth to 11 yr 10 mg/kg IV every 8 hr for 14-28 days. Administer w/in 30-120 min.
Hypersensitivity. Non-controlled arterial HTN, pheochromocytoma, carcinoid, thyrotoxicosis, bipolar depression, schizoaffective disorder, acute episodes of dizziness; SSRIs, TCAs, serotonin 5-HT1 receptor agonists (triptanes), directly & indirectly acting sympathomimetics (including adrenergic bronchodilators, pseudoephedrine, phenylpropanolamine), vasopressors (epinephrine, norepinephrine), dopaminergic compds (dopamine, dobutamine), pethidine or buspirone. Patients receiving inhibitors of monoamine oxidases A or B (eg, phenelzine, isocarboxazid, selegiline, moclobemide) or w/in 2 wk after administration.
Special Precautions
Not indicated for gm -ve causative agents. DM or other conditions characterized by impaired glucose tolerance. Reversible myelosuppression. Patients w/ high risk of life-threatening systemic infections. Severe anemia (use >28 days); lactic acidosis; pseudomembranous colitis; Clostridium difficile-associated diarrhea; peripheral & optic neuropathy may occur. History of seizures or risk occurrence. Monitor CBC for patients w/ preexisting anemia, granulocytopenia, thrombocytopenia; increased risk of bleeding occurrence; previously identified myelosuppression or receiving linezolid for >2 wk or once a wk. Refrain intake of tyramine-enriched food. Severe renal failure & liver injury. Concomitant use w/ serotonegic drugs including antidepressants (SSRIs). Pregnancy & lactation.
Adverse Reactions
Oral & vag candidiasis or fungal infections; headache, taste perversion (metallic aftertaste); diarrhea, nausea, vomiting; abnormal liver function tests; increased AST, ALT, LDH, alkaline phosphatase, BUN, creatine phosphokinase, lipase, amylase or glucose w/o starvation; decreased total protein, albumin, Na & Ca; increased/decreased K or bicarbonate; increased neutrophil & eosinophil counts; decreased Hb, hematocrit or erythrocytes count; increased/decreased platelet or leukocyte count. Anemia, leukopenia, thrombocytopenia, pancytopenia, myelosuppression; anaphylaxis, trophic & metabolic disorders (lactic acidosis); peripheral neuropathy, seizures, serotonin syndrome; optic neuropathy; angioedema, skin blisters eg, Stevens-Johnson syndrome.
Drug Interactions
Increased ave systolic arterial pressure w/ pseudoephedrine & phenylpropanolamine.
MIMS Class
Other Antibiotics
ATC Classification
J01XX08 - linezolid ; Belongs to the class of other antibacterials. Used in the systemic treatment of infections.
Linelid soln for infusion 2 mg/mL
300 mL x 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in